Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 Trial

被引:0
|
作者
Kathryn Therese Mngadi
Silvia Maarschalk
Anneke C. Grobler
Leila E. Mansoor
Janet A. Frohlich
Bernadette Madlala
Nelisiwe Ngcobo
Salim S. Abdool Karim
Quarraisha Abdool Karim
机构
[1] University of KwaZulu-Natal,Centre for the AIDS Program of Research in South Africa, Doris, Duke Medical Research Institute
[2] Nelson R Mandela School of Medicine,Department of Epidemiology, Mailman School of Public Health
[3] Columbia University,undefined
来源
AIDS and Behavior | 2014年 / 18卷
关键词
Adherence; Partner disclosure; HIV prevention; Microbicides; Pre-exposure prophylaxis;
D O I
暂无
中图分类号
学科分类号
摘要
Young women in sub-Saharan Africa are disproportionately affected by HIV, making the development of women initiated and controlled methods of prevention, including microbicides, a priority. Adherence is pivotal to microbicide efficacy and partner related factors are known to impact adherence. An analysis of disclosure of gel use to sexual partners and adherence in CAPRISA 004 women was conducted to better understand this relationship. Partner disclosure was significantly associated with a modest 4.2 % increased adherence (71.0 vs. 66.8 %, p = 0.03). Most women rated the experience of disclosure as positive, despite 6.7 % of partners expressing a negative reaction.Participants who disclosed were more likely to reside with their regular partner (14.4 vs. 8.4 %; p = 0.01) and reported consistent condom use at baseline (32.9 vs. 20.9 %; p < 0.01). Partner disclosure needs to be better understood as a potential facilitator or barrier to microbicide adherence.
引用
收藏
页码:849 / 854
页数:5
相关论文
共 50 条
  • [21] Preservation HIV-1-Specific IFNγ+CD4+T-Cell Responses in Breakthrough Infections After Exposure to Tenofovir Gel in the CAPRISA 004 Microbicide Trial
    Mureithi, Marianne W.
    Poole, Danielle
    Naranbhai, Vivek
    Reddy, Shabashini
    Mkhwanazi, Nompumelelo P.
    Sibeko, Sengeziwe
    Werner, Lise
    Karim, Quarraisha Abdool
    Karim, Salim Abdool
    Ndung'u, Thumbi
    Altfeld, Marcus
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 60 (02) : 124 - 127
  • [22] Reply to 'Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial'
    O'Hagan, Justin J.
    Hernan, Miguel A.
    Walensky, Rochelle P.
    Lipsitch, Marc
    AIDS, 2012, 26 (17) : 2262 - 2263
  • [23] Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
    Matthews, Lynn T.
    Sibeko, Sengeziwe
    Mansoor, Leila E.
    Yende-Zuma, Nonhlanhla
    Bangsberg, David R.
    Karim, Quarraisha Abdool
    PLOS ONE, 2013, 8 (03):
  • [24] Co-enrollment in multiple HIV prevention trials - Experiences from the CAPRISA 004 Tenofovir gel trial
    Karim, Quarraisha Abdool
    Kharsany, Ayesha B. M.
    Naidoo, Kasavan
    Yende, Nonhlanhla
    Gengiah, Tanuja
    Omar, Zaheen
    Arulappan, Natasha
    Mlisana, Koleka P.
    Luthuli, Londiwe R.
    Karim, Salim S. Abdool
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 (03) : 333 - 338
  • [25] HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial
    Garrett, Nigel J.
    Werner, Lise
    Naicker, Nivashnee
    Naranbhai, Vivek
    Sibeko, Sengeziwe
    Samsunder, Natasha
    Gray, Clive
    Williamson, Carolyn
    Morris, Lynn
    Abdool-Karim, Quarraisha
    Abdool-Karim, Salim S.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 68 (01) : 55 - 61
  • [26] No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial
    Chopera, Denis R.
    Mann, Jaclyn K.
    Mwimanzi, Philip
    Omarjee, Saleha
    Kuang, Xiaomei T.
    Ndabambi, Nonkululeko
    Goodier, Sarah
    Martin, Eric
    Naranbhai, Vivek
    Karim, Salim Abdool
    Karim, Quarraisha Abdool
    Brumme, Zabrina L.
    Ndung'u, Thumbi
    Williamson, Carolyn
    Brockman, Mark A.
    PLOS ONE, 2013, 8 (08):
  • [27] Effects of Partnership Change on Microbicide Gel Adherence in a Clinical Trial (HPTN 035)
    Pamina M. Gorbach
    Clifton W. Kelly
    Joleen A. Borgerding
    Gita Ramjee
    Tchangani Tembo
    Newton Kumwenda
    Petina Musara
    Sarah Roberts
    Lisa Maslankowski
    AIDS and Behavior, 2014, 18 : 855 - 861
  • [28] Effects of Partnership Change on Microbicide Gel Adherence in a Clinical Trial (HPTN 035)
    Gorbach, Pamina M.
    Kelly, Clifton W.
    Borgerding, Joleen A.
    Ramjee, Gita
    Tembo, Tchangani
    Kumwenda, Newton
    Musara, Petina
    Roberts, Sarah
    Maslankowski, Lisa
    AIDS AND BEHAVIOR, 2014, 18 (05) : 855 - 861
  • [29] Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial
    Giguere, Rebecca
    Rael, Christine Tagliaferri
    Sheinfil, Alan
    Balan, Ivan C.
    Brown, William, III
    Ho, Titcha
    Dolezal, Curtis
    Leu, Cheng-Shiun
    Liu, Albert
    Mayer, Kenneth H.
    Lama, Javier R.
    McGowan, Ian
    Carballo-Dieguez, Alex
    Cranston, Ross D.
    AIDS AND BEHAVIOR, 2018, 22 (02) : 388 - 401
  • [30] No Evidence for Selection of HIV-1 with Enhanced Gag-Pro or Nef Function Among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial
    Chopera, D. R.
    Mann, J.
    Mwimanzi, P.
    Omarjee, S.
    Kuang, X.
    Ndabambi, N.
    Goodier, S.
    Martin, E.
    Naranbhai, V.
    Karim, S. Abdool
    Karim, Q. Abdool
    Brumme, Z.
    Ndung'u, T.
    Williamson, C.
    Brockman, M.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (11) : A82 - A82